

# Evgeny Klyuchnikov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2110889/publications.pdf>

Version: 2024-02-01

44  
papers

1,105  
citations

430874

18  
h-index

395702

33  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1668  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
2	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. <i>Experimental Hematology</i> , 2009, 37, 791-798.	0.4	90
3	Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous/Allogeneic Tandem Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 398-404.	2.0	85
4	CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 382-386.	2.0	74
5	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
6	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
7	Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. <i>British Journal of Haematology</i> , 2012, 159, 172-181.	2.5	52
8	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
9	Current Status and Perspectives of Tyrosine Kinase Inhibitor Treatment in the Posttransplant Period in Patients with Chronic Myelogenous Leukemia (CML). <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 301-310.	2.0	36
10	Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. <i>Experimental Hematology</i> , 2010, 38, 1261-1271.	0.4	32
11	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. <i>British Journal of Haematology</i> , 2018, 182, 418-422.	2.5	28
12	The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004. <i>Annals of Hematology</i> , 2009, 88, 1237-1247.	1.8	25
13	Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia. <i>Acta Haematologica</i> , 2009, 122, 6-10.	1.4	25
14	Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1399-1405.	2.0	24
15	Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. <i>Leukemia and Lymphoma</i> , 2010, 51, 1837-1843.	1.3	22
16	Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1450-1463.	1.3	21
17	Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. <i>Acta Haematologica</i> , 2011, 126, 30-39.	1.4	21
18	TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 630429.	4.8	19

#	ARTICLE	IF	CITATIONS
19	Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 551-558.	1.3	16
20	Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2015, 134, 146-154.	1.4	15
21	Purification of CD4+ T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 374-383.	2.0	14
22	Enhanced Immune Reconstitution of $\gamma\delta$ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 841-850.	1.2	13
23	Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. <i>European Journal of Haematology</i> , 2021, 106, 606-615.	2.2	12
24	Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. <i>Bone Marrow Transplantation</i> , 2021, 56, 2834-2841.	2.4	12
25	Safety of conditioning agents for allogeneic haematopoietic transplantation. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 305-315.	2.4	11
26	Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. <i>Cancers</i> , 2020, 12, 3098.	3.7	10
27	Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 1478-1481.	2.4	9
28	Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3437-3437.	1.4	7
29	Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 510-512.	2.4	6
30	Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 374.e1-374.e9.	1.2	4
31	Sensitising leukemic cells by targeting microenvironment. <i>Leukemia and Lymphoma</i> , 2009, 50, 319-320.	1.3	3
32	Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients.. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	3
33	Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. <i>Bone Marrow Transplantation</i> , 2020, 55, 1817-1820.	2.4	1
34	Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2011, 118, 501-501.	1.4	1
35	Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia. <i>Acta Haematologica</i> , 2011, 125, 175-178.	1.4	0
36	Second Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 4308-4308.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting.. Blood, 2010, 116, 1300-1300.	1.4	0
38	Application of Nelarabine for Refractory or Relapsed T-Lymphatic Neoplasms In Adults Before Allogeneic Stem Cell Transplantation.. Blood, 2010, 116, 3496-3496.	1.4	0
39	Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 4467-4467.	1.4	0
40	Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients. Blood, 2011, 118, 3024-3024.	1.4	0
41	Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.. Blood, 2012, 120, 3055-3055.	1.4	0
42	Allogeneic Stem Cell Transplantation As Salvage Therapy for First Relapse after Autografting in Multiple Myeloma Patients. Blood, 2016, 128, 4619-4619.	1.4	0
43	Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients. Blood, 2021, 138, 4909-4909.	1.4	0
44	Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation. Blood, 2021, 138, 3897-3897.	1.4	0